Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)

Recruiting N/A Interventional Study
Atrial Fibrillation HFpEF - Heart Failure With Preserved Ejection Fraction
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
436 (estimated)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Symptomatic paroxysmal or persistent atrial fibrillation * CHADS2-VASc score≥ 2 * Conform to the diagnosis of HFpEF 1. NYHA II-IV level; 2. Left ventricular ejection fraction (LVEF)≥ 50%; 3. NT-proBNP≥ 300 pg/mL under sinus rhythm or NT-proBNP≥ 600 pg/mL under atrial fi…
Contacts

Hailei Liu, PhD

+86-18094226858

liuhailei@njmu.edu.cn

CONTACT

Nan Wu, MD

+86-18351977986

wunannjmu@163.com

CONTACT